Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients-Reference-Cited by-同舟云学术

Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients

Published:2018-12 Issue: Volume:57 Page:60-67
ISSN:1877-7821
Container-title:Cancer Epidemiology
language:en
Short-container-title:Cancer Epidemiology

Author:

Degeling Koen^ORCID,Franken Mira D.,May Anne M.,van Oijen Martijn G.H.,Koopman Miriam,Punt Cornelis J.A.,IJzerman Maarten J.^ORCID,Koffijberg Hendrik

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Epidemiology

Reference31 articles.

1. American society of clinical oncology guidance statement: the cost of Cancer care;Meropol;J. Clin. Oncol.,2009

2. Economic burden of cancer across the European Union: a population-based cost analysis;Luengo-Fernandez;Lancet Oncol.,2013

3. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS);Cherny;Ann. Oncol.,2015

4. American society of clinical oncology statement: a conceptual framework to assess the value of Cancer treatment options;Schnipper;J. Clin. Oncol.,2015

5. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA task force report;Ramsey;Value Health,2005

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care;PharmacoEconomics;2024-09-07

2. Predicting the Population Health Economic Impact of Current and New Cancer Treatments for Colorectal Cancer: A Data-Driven Whole Disease Simulation Model for Predicting the Number of Patients with Colorectal Cancer by Stage and Treatment Line in Australia;Value in Health;2024-07

3. Discrete Event Simulation to Incorporate Infusion Wait-Time When Assessing Cost-Effectiveness of a Chimeric-Antigen Receptor T Cell Therapy;Value in Health;2024-04

4. Cost-Effectiveness of Routine Monitoring of Long-Term Conditions in Primary Care: Informing Decision Modelling with a Systematic Review in Hypertension, Type 2 Diabetes and Chronic Kidney Disease;PharmacoEconomics - Open;2024-02-23

5. DESnets: A Graphical Representation for Discrete Event Simulation and Cost-Effectiveness Analysis;Mathematics;2023-03-26